Safety and efficacy of P2Y₁₂ inhibitor monotherapy in patients undergoing percutaneous coronary interventions

References

• Capodanno D, Alfonso F, Levine GN, et al. ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. J Am Coll Cardiol. 2018;72(23Pt A):2915–2931.
   PubMed Web of Science ®Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–122.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–260.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016;134(10):e123–55.
   PubMed Web of Science ®Google Scholar
• Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334(17):1084–1089. DOI:10.1056/NEJM199604253341702
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339(23):1665–1671. DOI:10.1056/NEJM199812033392303
   PubMed Web of Science ®Google Scholar
• Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998;98(20):2126–2132. DOI:10.1161/01.CIR.98.20.2126
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation. 1998;98(16):1597–1603. DOI:10.1161/01.CIR.98.16.1597
   PubMed Web of Science ®Google Scholar
• Bossavy JP, Thalamas C, Sagnard L, et al. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood. 1998;92(5):1518–1525. DOI:10.1182/blood.V92.5.1518
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102(6):624–629.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–1516. DOI:10.1016/j.jacc.2006.11.044
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Alexopoulos D, et al. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y(12) Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC Cardiovasc interventions. 2019;12(16):1521–1537. DOI:10.1016/j.jcin.2019.03.034
   PubMed Web of Science ®Google Scholar
• Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12(1):30–47.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361(11):1045–1057. DOI:10.1056/NEJMoa0904327
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007;357(20):2001–2015. DOI:10.1056/NEJMoa0706482
   PubMed Web of Science ®Google Scholar
• Moon JY, Franchi F, Rollini F, et al. The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. Expert Rev Hematol. 2018;11(1):5–12.
   PubMed Web of Science ®Google Scholar
• Park Y, Franchi F, Rollini F, et al. Dual antiplatelet therapy after coronary stenting. Expert Opin Pharmacother. 2016;17(13):1775–1787.
   PubMed Web of Science ®Google Scholar
• Buccheri S, Capodanno D, James S, et al. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opin Drug Saf. 2019;18(12):1171–1189.
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk. Eur Heart J. 2019;40(31):2632–2653. DOI:10.1093/eurheartj/ehz372
   PubMed Web of Science ®Google Scholar
• Moon JY, Franchi F, Rollini F, et al. Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy. Prog Cardiovasc Dis. 2018;60(4–5):478–490.
   PubMed Web of Science ®Google Scholar
• Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017;38(14):1034–1043.
   PubMed Web of Science ®Google Scholar
• Benenati S, Galli M, De Marzo V, et al. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35,785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Pharmacother. 2020. DOI:10.1093/ehjcvp/pvaa001
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies. Circulation. 2017;136(20):1955–1975. DOI:10.1161/CIRCULATIONAHA.117.031164
   PubMed Web of Science ®Google Scholar
• Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016;13(1):11–27.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Mehran R, Valgimigli M, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018;15(8):480–496. DOI:10.1038/s41569-018-0049-1.
   PubMed Web of Science ®Google Scholar
• O’Donoghue Michelle L, Murphy Sabina A, Sabatine Marc S. The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention. Circulation. 2020;142(6):538–545. DOI:10.1161/CIRCULATIONAHA.120.046251.
   PubMed Web of Science ®Google Scholar
• Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des. 2006;12(10):1255–1259.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74(4):597–607.
   PubMed Web of Science ®Google Scholar
• Baber U, Zafar MU, Dangas G, et al. Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy. J Am Coll Cardiol. 2020;75(6):578. DOI:10.1016/j.jacc.2019.11.056
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Garcia E, et al. Effects of edoxaban on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel: results of the EDOX-APT study. Thromb Haemost. 2020;120(1):83–93. DOI:10.1055/s-0039-1695772
   PubMed Web of Science ®Google Scholar
• Armstrong PCJ, Leadbeater PD, Chan MV, et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost. 2011;9(3):552–561. DOI:10.1111/j.1538-7836.2010.04160.x
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Faz G, et al. Pharmacodynamic effects of vorapaxar in prior myocardial infarction patients treated with potent oral P2Y(12) receptor inhibitors with and without aspirin: results of the VORA-PRATIC study. J Am Heart Assoc. 2020;9(8):e015865. DOI:10.1161/JAHA.120.015865
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Kairouz V, et al. Pharmacodynamic effects of vorapaxar in patients with and without diabetes mellitus: results of the OPTIMUS-5 study. JACC Basic Transl Sci. 2019;4(7):763–775. DOI:10.1016/j.jacbts.2019.07.011
   PubMedGoogle Scholar
• Isles C, Norrie J, Paterson J, et al. Risk of major gastrointestinal bleeding with aspirin. Lancet. 1999;353(9147):148–150.
   PubMed Web of Science ®Google Scholar
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–1339. DOI:10.1016/S0140-6736(96)09457-3
   PubMed Web of Science ®Google Scholar
• Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y(12) inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395(10235):1487–1495. DOI:10.1016/S0140-6736(20)30315-9
   PubMed Web of Science ®Google Scholar
• Capodanno D, Huber K, Mehran R, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI. J Am Coll Cardiol. 2019;74(1):83. DOI:10.1016/j.jacc.2019.05.016
   PubMed Web of Science ®Google Scholar
• Andreotti F, Testa L, Biondi-Zoccai GG, et al. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27(5):519–526.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Bhatt DL, Eikelboom JW, et al. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol. 2020;17(4):242–257. DOI:10.1038/s41569-019-0314-y
   PubMed Web of Science ®Google Scholar
• Weitz JI, Angiolillo DJ, Geisler T, et al. Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence. Thromb Haemost. 2020;120(8):1147–1158.
   PubMedGoogle Scholar
• Galli M, Andreotti F, Savarese G, et al. Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute? Eur Heart J Cardiovasc Pharmacother. 2019;5(1):55–56. DOI:10.1093/ehjcvp/pvy039
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ. Dual antithrombotic therapy for atrial fibrillation and PCI. Lancet. 2019;394(10206):1300–1302.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Chrolavicius S, et al. Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation. N Engl J Med. 2009;360(20):2066–2078. DOI:10.1056/NEJMoa0901301
   PubMed Web of Science ®Google Scholar
• Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126(10):1185–1193. DOI:10.1161/CIRCULATIONAHA.112.114967
   PubMed Web of Science ®Google Scholar
• Angiolillo Dominick J, Goodman Shaun G, Bhatt Deepak L, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2018;138(5):527–536. DOI:10.1161/CIRCULATIONAHA.118.034722
   PubMed Web of Science ®Google Scholar
• Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–1115. DOI:10.1016/S0140-6736(12)62177-1
   PubMed Web of Science ®Google Scholar
• Galli M, Andreotti F, D’Amario D, et al. Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: a critical appraisal. Int J cardiol Heart vasculature. 2020;28:100524.
   PubMed Web of Science ®Google Scholar
• Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65(16):1619–1629. DOI:10.1016/j.jacc.2015.02.050
   PubMed Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–1524. DOI:10.1056/NEJMoa1817083
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–1343. DOI:10.1016/S0140-6736(19)31872-0
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–2434. DOI:10.1056/NEJMoa1611594
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–1524. DOI:10.1056/NEJMoa1708454
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29–38. DOI:10.1016/S0140-6736(09)60738-8
   PubMed Web of Science ®Google Scholar
• Gibson CM, Pinto DS, Chi G, et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin k antagonist treatment strategy. Circulation. 2017;135(4):323–333. DOI:10.1161/CIRCULATIONAHA.116.025783
   PubMed Web of Science ®Google Scholar
• Kerneis M, Gibson CM, Chi G, et al. Effect of procedure and coronary lesion characteristics on clinical outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial. JACC Cardiovasc interventions. 2018;11(7):626–634. DOI:10.1016/j.jcin.2017.11.009
   PubMed Web of Science ®Google Scholar
• Oldgren J, Steg PG, Hohnloser SH, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019;40(19):1553–1562. DOI:10.1093/eurheartj/ehz059.
   PubMed Web of Science ®Google Scholar
• Windecker S, Lopes RD, Massaro T, et al. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention: insights from the AUGUSTUS trial. Circulation. 2019;140(23):1921–1932. DOI:10.1161/CIRCULATIONAHA.119.043308
   PubMed Web of Science ®Google Scholar
• Lopes Renato D, Leonardi S, Wojdyla Daniel M, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. 2020;141(9):781–783. DOI:10.1161/CIRCULATIONAHA.119.044584.
   PubMed Web of Science ®Google Scholar
• Alexander John H, Wojdyla D, Vora Amit N, et al. Risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention. Circulation. 2020;141(20):1618–1627. DOI:10.1161/CIRCULATIONAHA.120.046534
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. Eur Heart J. 2020. DOI:10.1093/eurheartj/ehaa617
   Google Scholar
• Tomoya H, Akira S, Daigo H, et al. Short-duration triple antithrombotic therapy for atrial fibrillation patients who require coronary stenting: results of the SAFE-A study. EuroIntervention. 2020;16(2):e164–e72. DOI:10.4244/EIJ-D-19-00920
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032–2042. DOI:10.1056/NEJMoa1908419.
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940–949.
   PubMed Web of Science ®Google Scholar
• Hahn J-Y, Song YB, Oh J-H, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428–2437. DOI:10.1001/jama.2019.8146
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414–2427. DOI:10.1001/jama.2019.8145
   PubMed Web of Science ®Google Scholar
• Kim B-K, Hong S-J, Cho Y-H, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407–2416. DOI:10.1001/jama.2020.7580
   PubMed Web of Science ®Google Scholar
• Franzone A, McFadden E, Leonardi S, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. J Am Coll Cardiol. 2019;74(18):2223–2234. DOI:10.1016/j.jacc.2019.08.1038
   PubMed Web of Science ®Google Scholar
• Anna F, Eugene PM, Sergio L, et al. Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. EuroIntervention. 2020 Oct 23;16(8):627-633.
   Web of Science ®Google Scholar
• Tomaniak M, Chichareon P, Klimczak-Tomaniak D, et al. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clin Res Cardiol. 2020;109(7):930–943. DOI:10.1007/s00392-019-01586-9
   PubMed Web of Science ®Google Scholar
• Tomaniak M, Chichareon P, Onuma Y, et al. Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial. JAMA Cardiol. 2019;4(11):1092–1101. DOI:10.1001/jamacardio.2019.3355
   PubMed Web of Science ®Google Scholar
• Baber U, Dangas G, Angiolillo DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020;41(37):3533–3545. DOI:10.1093/eurheartj/ehaa670
   PubMed Web of Science ®Google Scholar
• Dangas G, Baber U, Sharma S, et al. Ticagrelor with or without aspirin after complex PCI. J Am Coll Cardiol. 2020;75(19):2414–2424. DOI:10.1016/j.jacc.2020.03.011
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Baber U, Sartori S, et al. Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2020;75(19):2403–2413. DOI:10.1016/j.jacc.2020.03.008
   PubMed Web of Science ®Google Scholar
• Kogame NGP, Modolo R, de Martino F, et al. Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable coronary artery disease: the ASET pilot study. JACC Cardiovasc interventions. 2020;13:2251–2262.
   Web of Science ®Google Scholar
• Collet J-P, Thiele H, Barbato E, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2020 Aug 29;ehaa575. doi: 10.1093/eurheartj/ehaa575. Online ahead of print.
   Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2020 Aug 29;ehaa612. doi: 10.1093/eurheartj/ehaa612. Online ahead of print.
   Web of Science ®Google Scholar
• Angiolillo DJBD, Cannon CP, Eikelboom JW, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a north american perspective – 2020 update. Circulation. 2018Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722.
   Google Scholar
• Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019;40(46):3757–3767.
   PubMed Web of Science ®Google Scholar
• Benenati S, Crimi G, Canale C, et al. Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug eluting stent implantation: a network Meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2020. DOI:10.1093/ehjcvp/pvaa127
   PubMedGoogle Scholar
• Baber UDG, Angiolillo DJ, Cohen DJ, et al. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020 Oct 1;41(37):3533–3545.
   PubMed Web of Science ®Google Scholar
• Lopes RD, Hong H, Harskamp RE, et al. Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. JAMA Cardiol. 2020;5(5):582–589. DOI:10.1001/jamacardio.2019.6175
   PubMed Web of Science ®Google Scholar
• Capodanno D, Di Maio M, Greco A, et al. Safety and efficacy of double antithrombotic therapy with non–vitamin k antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta‐analysis. J Am Heart Assoc. 2020 Aug 18;9(16):e017212. doi: 10.1161/JAHA.120.017212.
   Web of Science ®Google Scholar
• Andò G, Costa F. Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol. 2020;302:95–102.
   PubMed Web of Science ®Google Scholar
• Galli M, Andreotti F, Porto I, et al. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace. 2020;22(4):538–546.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Collet JP, Haude M, et al. Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: A Summary of the joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Eur Heart J. 2018;39(31):2847–2850.
   PubMedGoogle Scholar
• Galli M, Andreotti F, D’Amario D, et al. Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. Eur Heart J Cardiovasc Pharmacother. 2020;6(2):128–129. DOI:10.1093/ehjcvp/pvz030
   PubMed Web of Science ®Google Scholar
• IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.
   PubMed Web of Science ®Google Scholar
• Levine GN, Jeong YH, Goto S, et al. Expert consensus document: world heart federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11(10):597–606. DOI:10.1038/nrcardio.2014.104
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Dual antiplatelet therapy guided by platelet function testing. Lancet. 2017;390(10104):1718–1720.
   PubMed Web of Science ®Google Scholar
• Moon JY, Franchi F, Rollini F, et al. Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Rev Clin Pharmacol. 2018;11(2):151–164. DOI:10.1080/17512433.2017.1353909
   PubMed Web of Science ®Google Scholar
• Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–1631. DOI:10.1056/NEJMoa1907096
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Rivas J, et al. Prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes: results of a randomized pharmacodynamic study in a feasibility investigation of rapid genetic testing. JACC Basic Transl Sci. 2020;5(5):419–428. DOI:10.1016/j.jacbts.2020.02.009
   PubMedGoogle Scholar
• Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel. JACC Cardiovasc Interv. 2020;13(5):606.
   PubMed Web of Science ®Google Scholar
• Lee H, Koo BK, Park KW, et al. A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: design and rationale of the harmonizing optimal strategy for treatment of coronary artery stenosis-extended antiplatelet monotherapy (HOST-EXAM) trial. Am Heart J. 2017;185:17–25.
   PubMed Web of Science ®Google Scholar
• Li Y, Jing Q, Wang B, et al. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Am Heart J. 2020;228:1–7.
   PubMed Web of Science ®Google Scholar